1	Emerging high-level ciprofloxacin-resistant Salmonella enterica serovar Typhi haplotype
2	H58 in travelers returning from India to the Republic of Korea
3	Eunkyung Shin ^{1,3} , Ae Kyung Park ¹ , Jungsun Park ¹ , Soojin Kim ¹ , Hyun Ju Jeong ¹ , Kyoungin
4	Na ² , Hyerim Lee ² , Jeong-hoon Chun ¹ , Kyu Jam Hwang ¹ , Chul-Joong Kim ³ , Junyoung Kim ¹
5	¹ Division of Bacterial Diseases, Korea Centers for Diseases Control and Prevention, Cheongju,
6	28159, Republic of Korea
7	² Division of Infectious Diseases Control, Korea Centers for Diseases Control and Prevention,
8	Cheongju, 28159, Republic of Korea
9	³ College of Veterinary Medicine, Chungnam National University, Daejeon, 34134, Republic of
10	Korea
11	
12	
10	
13	
14	
15	Corresponding author: Junyoung Kim
16	Division of Bacterial Diseases, Center for Laboratory Control of Infectious Diseases, Korea
17	Centers for Diseases Control and Prevention, Cheongju-si, Chungcheongbuk-do, 28159,
18	Republic of Korea
19	Tel: +82-43-719-8116; Fax: +82-43-719 8109; E-mail: jun49@hanmail.net

20 Abstract

21 In Korea, typhoid fever is a rare disease due to improved living standards. However, this disease 22 remains a major burden in developing countries and regions, such as India and Southeast Asia, In 23 this study, we isolated *Salmonella* Typhi (S. Typhi) from eight typhoid patients, travelers 24 returning from India. Isolated strains characterized with antimicrobial susceptibility profile and 25 whole genome sequencing (WGS) analysis. All strains were resistant to nalidixic acid and azithromycin. Among them, four isolates were 26 highly resistant to ciprofloxacin (MIC \geq 32 µg/ml) and never confirmed in Korea *PulseNet* DB. 27 On the basis of the WGS, we found that the ciprofloxacin-resistant strain belonged to global 28 dominant multi-drug resistant (MDR) genotype, haplotype H58 (SNP glpA C1047T, SptP protein 29 30 Q185* (premature stop codon)) not harbour MDR plasmid. They have H58-associated SNPs in

membranes and metabolism genes, including *yhdA*, *yajI*, *hyaE*, *tryE*, *rlpB* and *metH*. Also,

32 Phylogenetic analysis showed that H58 strains were assigned sublineage II, and the non-H58

33 strains were closely related to haplotype H50.

High-level ciprofloxacin-resistant *S*. Typhi haplotype H58 in Korea was first confirmed as influx
from overseas by travelers. This study provides information about intercontinental drug-resistant
transmission between countries and suggests that travelers need to be careful about personal
hygiene.

39 Introduction

Typhoid fever, caused by *Salmonella enterica* serovar Typhi (*S*. Typhi), is a systemic disease
that causes gastroenteritis, fever, and severe diarrhea. *S*. Typhi is a human-specific pathogen
transmitted by the ingestion of contaminated water or food[1]. This disease remains a major
burden in developing countries, such as India, Pakistan, and Egypt, and causes 216,000
deaths/year worldwide[2].

Multidrug-resistant (MDR) S. Typhi displaying resistance to chloramphenicol, ampicillin, and 45 trimethoprim has been reported in epidemic countries since the 1960s. Resistance to 46 fluoroquinolones and third-generation cephalosporins was recently demonstrated in the 2000s, 47 and more than 90% of south Asian S. Typhi strains have decreased susceptibility to ciprofloxacin 48 49 (CIP)[3]. SNP-based analysis schemes have been developed by stratifying the S. Typhi population by haplotype[4]. According to Wong et al., over the past two decades, a dominant 50 MDR lineage, S. Typhi haplotype H58, initially defined by the SNP glpA-C1047T, has become 51 52 prevalent worldwide. In particular, decreased susceptibility of S. Typhi to fluoroquinolones, 53 which is frequently reported in Africa and Asia[5,6], is associated with the H58 sublineage. 54 In developed countries, typhoid generally occurs in only individuals who have travelled to endemic countries and immigrants from those regions. In Switzerland, quinolone-resistant 55 56 typhoid infection was reported in a traveler returning from India[7], and MDR S. Typhi isolates related to travel to Pakistan were detected in the United Kingdom[8]. Typhoid fever is 57 uncommon in the Republic of Korea; approximately 156 cases are reported yearly to the Korea 58 National Surveillance System[9]. In 2017, we first isolated H58 S. Typhi during an outbreak 59

- 60 involving international travelers returning from India. To investigate the transmission route and
- 61 characterize the isolates, we analysed the H58 strain using whole-genome sequencing.

62 Materials and Methods

63 Clinical isolates

- 64 Stool and blood samples of patients were processed according to the standard bacterial culture
- 65 method; bacterial identification was performed using a VITEK-II automated system
- 66 (bioMérieux, Marcy l'Etoile, France), and serotyping of Salmonella was carried out according to
- 67 the Kauffmann-White scheme using antisera (BD Biosciences, Frankland Lakes, NJ, USA). The
- 68 clinical samples were collected anonymously by *EnterNet* Korea, National gastrointestinal
- 69 infections disease surveillance network.

70 Antimicrobial resistance profile

71 Antimicrobial susceptibilities and minimum inhibitory concentrations (MICs) were determined

vising the broth microdilution method with 16 antibiotics and customized KRCDC1F Sensititre

73 panels (Trek Diagnostic Systems, OH, USA) in accordance with the guidelines established by

the Clinical and Laboratory Standards Institute (CLSI). The antimicrobial agents tested were

75 ampicillin, ampicillin–sulbactam, amoxicillin–clavulanic acid, cephalothin, cefoxitin,

76 ceftriaxone, cefotaxime, nalidixic acid, ciprofloxacin, tetracycline, chloramphenicol, imipenem,

streptomycin, gentamicin, amikacin, and trimethoprim–sulfamethoxazole.

78 Whole-genome sequencing

79 Genomic DNA was isolated with DNA Blood and Tissue Kit (Qiagen, Hombrechtikon,

80 Switzerland). Whole-genome sequencing was performed on a MiSeq platform (Illumina Inc.,

- 81 San Diego, CA) with a v.2 (500 cycles with 2 X 250-nt reads) kit. The existence and mutations
- of antibiotic resistance genes and plasmids were determined using Bacterial Analysis Pipeline

83	version 1.0.4. (Illumina BaseSpace Labs, https://basespace.illumina.com/). Other alleles in
84	virulence- and adaptation-related genes were identified using the Geneious Prime 2019.2.1
85	program.

86 *wgSNP and wgMLST analysis*

- 87 Paired-end reads were performed with the wgSNP module of BioNumerics v7.6 software
- 88 (Applied Maths) and mapped to the *S*. Typhi reference genome CT18 (AL513382). By choosing
- the default strict filtering option with minimum coverage at x30 base quality, strain-specific
- 90 SNPs were determined. Then, whole-genome multilocus sequence typing (wgMLST) was
- analysed using 15874 loci with the open data set in the wgMLST module. By advanced cluster
- 92 analysis, a minimum spanning tree was constructed.

94 **Results**

95 *Case description*

96	In July and August 2017, eight patients were found to be infected with typhoid fever. Five
97	patients had volunteered and travelled in the Northwest region of India (New Delhi, Amritsar,
98	Dharamshala, and Agra) on July 19-27th (group A). The first case occurred on July 22nd and
99	was accompanied by fever, chills, watery diarrhea, headache, and sweating. The onset of the
100	second case occurred on July 28th. After returning to Korea, three patients showed symptoms
101	such as fever, chills, anorexia and stomach-ache on the 6th ($n=2$) and 13th ($n=1$) of August. In
102	August, another group travelled along the same route (group B). Three tourists were reported as
103	having typhoid fever on August 18th (Figure 1).

104 Antibiotic resistance profiles

105 All strains were resistant to nalidixic acid (NAL; minimum inhibitory concentration (MIC)

 $\geq 128 \ \mu g/ml$) and azithromycin (AZI; MIC $\geq 8 \ \mu g/ml$). Only four isolates (1 from group A and 3

107 from group B) were highly resistant to ciprofloxacin (MIC \ge 32 µg/ml) (Table 1). Furthermore,

analysis of the antimicrobial gene mutations of the CIP-resistant isolates revealed two mutations

in the gyrA gene (Ser83 \rightarrow Phe (S83F) and Asp87 \rightarrow Asn) and a parC mutation (Ser80 \rightarrow IIe). In

addition, the analysis of plasmid-mediated quinolone resistance (PMQR) determinants indicated

111 that the CIP-resistant isolates contained the aac(6')-Iaa gene. The non-H58 strain had a mutation

112 in gyrA (S83F) and a PMQR gene (aac(6')-Iaa) on the plasmid and replicon type (IncFIB

113 (pHCM2)).

114 *Whole-genome sequencing analysis*

- All eight isolates indicated that the high-level CIP-resistant strains belonged to haplotype H58,
- 116 while the CIP-susceptible strains did not. The CIP-resistant strains had the typical features of
- 117 H58: SNPs in *glpA* at nucleotide 252 and position 2,348,902 in *S*. Typhi CT18 (C1047T) and
- 118 *SptP* protein Q185* (premature stop codon). Maximum likelihood phylogeny was inferred from
- 119 1577 SNPs (Figure 2A). SNP-based analysis distinguished the *S*. Typhi isolates by haplotype.
- 120 The H58 strains formed a tight cluster and belonged to sub-lineage II, with comparative strains
- 121 from India, Viet nam, Sri lanka and Lebanon. The non-H58 strains were closely related to
- haplotype H50. A minimum spanning tree (Figure 2B) based on wgMLST showed similar
- results, but it is difficult to distinguish between H58 sub-lineages.

125 Discussion

126 In Korea, six travel-associated cases (in addition to this outbreak) and 304 S. Typhi isolates have been sporadically identified over the past decade, [10]. The previous travel cases were 127 128 associated with China (n=2), Japan (n=1), Indonesia (n=2), and Russia (n=1). Therefore, this 129 report describes the first Korean S. Typhi H58 outbreak following international travel to India. India is a well-known geographical source of H58 with high CIP resistance[11]. 130 Since the 1960s, antimicrobial-resistant S. Typhi has been prevalent worldwide. NAL-resistant 131 S. Typhi is frequently isolated in India, and high-level CIP-resistant S. Typhi was recently 132 isolated from a domestic patient[12]. In 2007, NAL-resistant S. Typhi strains were reported for 133 the first time in Korea and did not respond to CIP as treatment[13]. These cases suggest an 134 135 alternative treatment as third-generation cephalosporins or AZI [6]. But the isolates showed resistance to not only NAL and CIP but also AZI. Moreover, the occurrence with extended 136 spectrum β -lactamases (ESBLs) harbouring CTX-M-15 and/or high resistance to quinolones has 137 138 been reported in other studies [14]. Therefore, an appropriate prescription based on surveillance will be required for future treatment. Continuous monitoring and data collection will be essential 139 to prevent the occurrence and treatment failure of antimicrobial-resistant S. Typhi. 140 As the dominant MDR lineage of S. Typhi, haplotype H58 has spread worldwide, particularly 141

in South Asia and Africa (3,4). In this research, we revealed H58 *S*. Typhi infection by
international travelers using WGS analysis. These H58 strains harboured a *glpA* gene and *SptP*protein mutation and triple point mutations in QRDR but lacked the MDR plasmid of the IncHI1
type. The most of H58 lineage relate with reduced globally susceptibility to fluoroquinolones and
harbouring IncHII [4]. Our results indicate that fluoroquinolone-resistant H58 with extending

- 147 other antimicrobial resistance is circulating in epidemic regions. Thus, continuous surveillance
- 148 will be needed to monitor intercontinental transmission of antimicrobial-resistant strains and
- support the global management of typhoid fever.

151 **References**

152	[1]	Crump JA, Mintz ED. Global Trends in Typhoid and Paratyphoid Fever. Clin Infect Dis
153		2010;50:241–6. https://doi.org/10.1086/649541.

- 154 [2] Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale V V., Ramani E, et al. Burden of
- 155 typhoid fever in low-income and middle-income countries: A systematic, literature-based
- update with risk-factor adjustment. Lancet Glob Heal 2014;2:e570–80.
- 157 https://doi.org/10.1016/S2214-109X(14)70301-8.
- 158 [3] Dyson ZA, Klemm EJ, Palmer S, Dougan G. Antibiotic Resistance and Typhoid. Clin
 159 Infect Dis 2019;68:S165–70. https://doi.org/10.1093/cid/ciy1111.
- 160 [4] Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, et al. Phylogeographical
- 161 analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies
- inter-and intracontinental transmission events. Nat Genet 2015;47:632–9.
- 163 https://doi.org/10.1038/ng.3281.
- 164 [5] Park SE, Pham DT, Boinett C, Wong VK, Pak GD, Panzner U, et al. The phylogeography
 165 and incidence of multi-drug resistant typhoid fever in sub-Saharan Africa. Nat Commun
 166 2018;9. https://doi.org/10.1038/s41467-018-07370-z.
- 167 [6] Thanh DP, Karkey A, Dongol S, Thi NH, Thompson CN, Rabaa MA, et al. A novel
- 168 ciprofloxacin-resistant subclade of h58. Salmonella typhi is associated with
- 169 fluoroquinolone treatment failure. Elife 2016;5:1–13. https://doi.org/10.7554/eLife.14003.
- 170 [7] Nüesch-Inderbinen M, Abgottspon H, Sägesser G, Cernela N, Stephan R. Antimicrobial
- 171 susceptibility of travel-related Salmonella enterica serovar Typhi isolates detected in

- 173 BMC Infect Dis 2015;15:1–5. https://doi.org/10.1186/s12879-015-0948-2.
- 174 [8] Chatham-Stephens K, Medalla F, Hughes M, Appiah GD, Aubert RD, Caidi H, et al.
- 175 Emergence of Extensively Drug-Resistant Salmonella Typhi Infections Among Travelers
- to or from Pakistan United States, 2016-2018. MMWR Morb Mortal Wkly Rep
- 177 2019;68:11–3. https://doi.org/10.15585/mmwr.mm6801a3.
- Korea Centers for Disease Control and Prevention (KCDC). Incidence of Legal infectious
 disease in national monitoring index n.d.
- 180 http://www.index.go.kr/potal/main/EachDtlPageDetail.do?idx_cd=1442.
- 181 [10] Korea Centers for Disease Control and Prevention (KCDC). Korea infectious disease

182 portal n.d. ttp://www.cdc.go.kr/npt/biz/npp/ist/bass/bassDissStatsMain.do.

- 183 [11] Wirth T. Massive lineage replacements and cryptic outbreaks of Salmonella Typhi in
- eastern and southern Africa. Nat Genet 2015;47:565–7. https://doi.org/10.1038/ng.3318.
- 185 [12] Renuka K, Sood S, Das BK, Kapil A. High-level ciprofloxacin resistance in Salmonella

186 enterica serotype Typhi in India. J Med Microbiol 2005;54:999–1000.

- 187 https://doi.org/10.1099/jmm.0.45966-0.
- 188 [13] Kim D-B, Kim S-H, Oh S-J, Kim D-K, Choi S-M, Kim M-S, et al. Three cases of
- 189 ciprofloxacin treatment failure in imported typhoid fever. Korean J Med 2009;77:377–81.
- 190 [14] Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of an
- 191 extensively drug-resistant Salmonella enterica serovar typhi clone harboring a

192	promiscuous plasmid encoding resistance to fluoroquinolones and third-generation
193	cephalosporins. MBio 2018;9:1-10. https://doi.org/10.1128/mBio.00105-18.
194	
195	
196	
197	

198 Funding

This work was supported by grant from the Korea Centers for Disease Control and Prevention
[Grant Number 4837-311-210]. We thank all the members of our laboratory for their feedback
and support.

202

203 Sequence data access

- 204 The whole-genome data of this study have been deposited in BioProject under number
- 205 PRJNA551786. The raw reads are available in the Sequence Read Archive (SRA) under

accession number SRR9616298-SRR9616305.

207

208 Ethical considerations

209 The Ethics committee of the first affiliated Korea Centers for Disease Control and Prevention

210 decided that Institutional Review Board approval was not required. Because patient information

211 was collected anonymously and confidential patient information was not included.

213 **Table**

Table 1. Antimicrobial resistance profiles and genomic analysis of the outbreak strains.

			MICs	Antimicrobial	Whole genome an	alysis			
ID No.	Traveler group	Date of diagnosis	CIP NAL AZI	Resistance	Mutants in QRDRs	Screening of PMQRs	Replicon type	MLST	haplotype
KRSAL17- 2203	A	22 July	0.25>128 8	NAL, AZI	gyrA(S83F)	aac(6')-laa	IncFIB(pHCM2)	ST2	H50
KRSAL17- 2207	A	6 Aug	0.25>128 8	NAL, AZI	gyrA(S83F)	aac(6')-laa	IncFIB(pHCM2)	ST2	H50
KRSAL17- 2205	A	6 Aug	0.25>128 8	NAL, AZI	gyrA(S83F)	aac(6')-laa	IncFIB(pHCM2)	ST2	H50
KRSAL17- 2206	A	13 Aug	0.25>128 8	NAL, AZI	gyrA(S83F)	aac(6')-laa	IncFIB(pHCM2)	ST2	H50
KRSAL17- 2218	В	18 Aug	>32 >128 16	CIP, NAL, AZI	gyrA(S83F,D87N) parC(S80I)	aac(6')-laa	-	ST1	H58
KRSAL17- 2204	A	28 July	>32 >128 16	CIP, NAL, AZI	gyrA(S83F,D87N) parC(S80I)	aac(6')-laa	-	ST1	H58
KRSAL17- 2217	В	18 Aug	>32 >128 16	CIP, NAL, AZI	gyrA(S83F,D87N) parC(S80I)	aac(6')-laa	-	ST1	H58
KRSAL17- 2216	В	18 Aug	>32 >128 16	CIP, NAL, AZI	gyrA(S83F,D87N) parC(S80I)	aac(6')-laa	-	ST1	H58

215

216

218 Figure legend

Figure 1. Epidemic curve of typhoid fever outbreak by date of onset.

220 Traveler group A cases are shown in red, and traveler group B cases are shown in green. Cases

of high-level ciprofloxacin-resistant *S*. typhi are marked with asterisks.

222

Figure 2. Whole-genome sequencing trees of *S*. Typhi isolates based on SNP and wgMLST
 analyses.

A, Maximum likelihood tree inferred from the 1577 identified SNPs and visualized by iTOL.

226 Comparative strains from the EBI (European Bioinformatics Institute) database and isolates are

227 marked in the following order: isolate name, Short Read Archive (SRA) accession number,

haplotype, and country. The numbers above the nodes represent data from bootstrap replicates.

B, Minimum spanning tree based on numerical values (15874 wgMLST loci). The branch

230 lengths are represented on a logarithmic scale. Traveler group A cases are shown by red circles,

and traveler group B cases are shown by green circles. The cluster of H58 strains is highlighted

in light grey, and the H50 strains are highlighted in light blue.









h

Travel group